Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for COVID-19 (SARS-CoV-2) Explicit IgG Antibody Revelation

Bijon Kumar Sil
,
Mohd. Raeed Jamiruddin
ORCID logo ,
Md. Ahsanul Haq
,
Mohib Ullah Khondoker
,
Nowshin Jahan
,
Shahad Saif Khandker
,
Tamanna Ali
,
Mumtarin Jannat Oishee
,
Taku Kaitsuka
ORCID logo ,
Masayasu Mie
ORCID logo ,
Kazuhito Tomizawa
ORCID logo ,
Eiry Kobatake
,
Mainul Haque
* ,
Nihad Adnan
* ORCID logo
Version 1 : Received: 18 April 2021 / Approved: 20 April 2021 / Online: 20 April 2021 (11:36:09 CEST)

How to cite: Sil, B. K.; Jamiruddin, M. R.; Haq, M. A.; Khondoker, M. U.; Jahan, N.; Khandker, S. S.; Ali, T.; Oishee, M. J.; Kaitsuka, T.; Mie, M.; Tomizawa, K.; Kobatake, E.; Haque, M.; Adnan, N. AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for COVID-19 (SARS-CoV-2) Explicit IgG Antibody Revelation. Preprints 2021, 2021040534. https://doi.org/10.20944/preprints202104.0534.v1 Sil, B. K.; Jamiruddin, M. R.; Haq, M. A.; Khondoker, M. U.; Jahan, N.; Khandker, S. S.; Ali, T.; Oishee, M. J.; Kaitsuka, T.; Mie, M.; Tomizawa, K.; Kobatake, E.; Haque, M.; Adnan, N. AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for COVID-19 (SARS-CoV-2) Explicit IgG Antibody Revelation. Preprints 2021, 2021040534. https://doi.org/10.20944/preprints202104.0534.v1

Abstract

Background: Flow-through dot-blot assay (FT-DBA) for SARS-CoV-2 specific IgG detection will provide a reliable and affordable immunoassay for the rapid serosurveillance against COVID-19. Method: SARS-CoV-2 antigens were immobilized on nitrocellulose membrane to capture IgG immunoglobulins, which were then detected with AuNP anti-human IgG. A total of 181 samples were characterized with in-house and commercial immunoassay. The positive panel consisted of RT-PCR positive samples from patients with both <14 days and >14 days from the onset of symptoms, while the negative panel contained samples collected either from the pre-pandemic era dengue patients from healthy donors during the pandemic period. Results: In-house ELISA selected a total of 79 true seropositive and 100 seronegative samples. The sensitivity of samples with <14 days using FT-DBA was 94.7% which increased to 100% for samples >14 days. The overall detection sensitivity and specificity were 98.8% and 98%, respectively, whereas the overall PPV and NPV were 97.6% and 99%. Moreover, comparative analysis between ELISA and FT-DBA revealed clinical agreement of Cohen’s Kappa value of 0.944. Conclusion: The assay can confirm past SARS-CoV-2 infection with high accuracy within 2 minutes compared to ELISA. It can help track SARS-CoV-2 disease progression, population screening, and vaccination response.

Keywords

COVID-19, SARS-CoV-2, Serological test, Sensitivity, Specificity, Serosurveillance.

Subject

Biology and Life Sciences, Virology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF Download Supplementary

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Get PDF Supplementary Files Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.